Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL3755368

CN(C)C(C)(CN)c1ccccc1.O=C(O)C(F)(F)F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.44
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP2C19 P33261 2/20 0.41
HIF1A Q16665 1/20 0.41
CYP1A2 P05177 3/20 0.40
CYP2D6 P10635 1/20 0.39
KCNN4 O15554 1/20 0.38
CYP3A4 P08684 1/20 0.38
RECQL P46063 1/20 0.38
KIF11 P52732 2/20 0.38
OPRM1 P35372 2/20 0.37
DRD3 P35462 2/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
MAPK1 P28482 1/20 0.37
CES1 P23141 2/20 0.37
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31646704 0.86 TAAR1 (0.58) TAAR1MAPTKMT2ACYP2C19HIF1A
Trifluoroacetic Acid SCHEMBL3755364 0.77 MAPT (0.50) MAPTKMT2ACYP2C19HIF1ACYP1A2
Trifluoroacetic Acid SCHEMBL28429332 0.74 CYP1A2 (0.50) MAPTKMT2ACYP2C19HIF1ACYP1A2
SCHEMBL3755365 0.74 HDAC3 (0.41) MAPTKMT2ACYP2C19HIF1AKCNN4
SCHEMBL23453194 0.71 TAAR1 (0.54) TAAR1MAPTKMT2ACYP2C19HIF1A
SCHEMBL1450491 0.71 TAAR1 (0.54) TAAR1MAPTKMT2ACYP2C19HIF1A
Trifluoroacetic Acid SCHEMBL29472278 0.70 POLQ (0.54) KMT2ACYP2C19CYP3A4NR1H3
Hydrochloric Acid SCHEMBL21631942 0.69 CYP1A2 (0.42) TAAR1MAPTKMT2ACYP2C19HIF1A
Trifluoroacetic Acid SCHEMBL31050230 0.69 MEN1 (0.42) KMT2ACYP2C19CYP3A4CES1NR1H2
Trifluoroacetic Acid SCHEMBL27504505 0.69 MAPT (0.44) MAPTKMT2ACYP2C19HIF1ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838518-B2 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders N.V. ORGANON (NL) 2010-11-23 US disclosed
EP-1476151-B1 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ORGANON NV (NL) 2008-07-16 EP disclosed
US-20050154023-A1 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders MERCK SHARP & DOHME B.V. (NL) 2005-07-14 US disclosed
EP-1476151-A1 1-ARYLSULFONYL-3-SUBSTITUED INDOLE AND INDOLINE DERIVATES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS Akzo Nobel N.V. (NL) 2004-11-17 EP disclosed
WO-2003068220-A1 1-ARYLSULFONYL-3-SUBSTITUTED INDOLE AND INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS AKZO NOBEL N.V. (NL) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154023-A1 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders TPH1, HTR1A, HTR1D TAAR1 183/4885MAPT 68/4885KMT2A 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.